AstraZeneca (AZN) News Today £109.22 -28.00 (-0.26%) As of 08/8/2025 12:57 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesSustainabilityBuy This Stock AZN Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period AstraZeneca (LON:AZN) Stock Price Passes Above 200 Day Moving Average - What's Next?August 8 at 5:45 AM | marketbeat.comAstraZeneca (LON:AZN) Earns "Hold" Rating from Deutsche Bank AktiengesellschaftAugust 1, 2025 | americanbankingnews.comAstraZeneca's (AZN) Hold Rating Reiterated at Deutsche Bank AktiengesellschaftJuly 31, 2025 | marketbeat.comAstraZeneca's (AZN) "Buy" Rating Reaffirmed at Shore CapitalJuly 31, 2025 | americanbankingnews.comShore Capital Sticks to Their Buy Rating for AstraZeneca (AZN)July 30, 2025 | theglobeandmail.comShore Capital Reaffirms "Buy" Rating for AstraZeneca (LON:AZN)July 30, 2025 | marketbeat.comAstraZeneca (AZN) Receives a Buy from TD CowenJuly 30, 2025 | theglobeandmail.comJefferies Reaffirms Their Hold Rating on AstraZeneca (AZN)July 30, 2025 | theglobeandmail.comAstraZeneca declares $1.03 dividendJuly 29, 2025 | msn.comAstraZeneca reports Q2 core EPS $2.17, up 12% at CERJuly 29, 2025 | msn.comAstraZeneca Books Record Quarterly Revenue as U.S, Oncology Boosts GrowthJuly 29, 2025 | msn.comAstraZeneca Stock Rises as US, Cancer Drugs Growth Lifts Q2 ResultsJuly 29, 2025 | msn.comAstraZeneca Books Record Quarterly Revenue as Oncology Boosts GrowthJuly 29, 2025 | msn.comFTSE 100 Live: Mixed start for stocks, Games Workshop and AstraZeneca climbJuly 29, 2025 | uk.investing.comAstraZeneca (AZN) Bets Big on U.S. with $50 Billion Manufacturing ExpansionJuly 29, 2025 | msn.comStocks to watch this week: Microsoft, Apple, Shell, AstraZeneca and HSBCJuly 28, 2025 | msn.comStocks to watch next week: Microsoft, Apple, Shell, AstraZeneca and HSBCJuly 25, 2025 | msn.comAstraZeneca’s AZD4144 Study Completion: Market Implications and InsightsJuly 24, 2025 | theglobeandmail.comAstraZeneca's rare immune disorder drug succeeds in advanced trialJuly 24, 2025 | msn.comAstraZeneca succeeds in late-stage trial for myasthenia gravis therapyJuly 24, 2025 | msn.comAstraZeneca (LSE:AZN) Commits US$50 Billion For US Expansion By 2030July 23, 2025 | finance.yahoo.comAstraZeneca (LSE:AZN) Anselamimab Shows Promise In AL Amyloidosis Despite Missing Main EndpointJuly 19, 2025 | finance.yahoo.comAstraZeneca announces Enhertu combination with pertuzumab granted BTD by FDAJuly 18, 2025 | finance.yahoo.comAstraZeneca therapy for clearing protein deposits fails main goal in late-stage studyJuly 17, 2025 | msn.comAstraZeneca’s anselamimab treatment fails to meet main trial goal; shares slipJuly 16, 2025 | uk.investing.comAstraZeneca’s rare disease drug falls short in late-stage trialJuly 16, 2025 | msn.comAstraZeneca drug lowers high blood pressure in late-stage study; shares riseJuly 15, 2025 | msn.comAstraZeneca PLC (AZN) Secures EU Approval for ImfinziJuly 15, 2025 | msn.comAstraZeneca Meets All Key Goals in Phase III Hypertension StudyJuly 15, 2025 | msn.comAstraZeneca (LSE:AZN) Unveils Promising Phase III Results For Baxdrostat In Hypertension TrialJuly 14, 2025 | finance.yahoo.comAstraZeneca slips Friday, underperforms marketJuly 11, 2025 | marketwatch.comAstraZeneca (AZN) Receives a Buy from Berenberg BankJuly 10, 2025 | theglobeandmail.comAstraZeneca (AZN) Receives a Hold from Deutsche BankJuly 10, 2025 | theglobeandmail.comAstraZeneca climbs Tuesday, outperforms marketJuly 8, 2025 | marketwatch.comTop Analyst Reports for T-Mobile, AstraZeneca & ComcastJuly 8, 2025 | msn.comAstraZeneca's (AZN) Hold Rating Reaffirmed at Deutsche Bank AktiengesellschaftJuly 8, 2025 | marketbeat.comAstraZeneca: Just What The Doctor OrderedJuly 8, 2025 | seekingalpha.comAstraZeneca (LSE:AZN) Wins EU Approval For Imfinzi In Muscle-Invasive Bladder CancerJuly 7, 2025 | finance.yahoo.comSummit Therapeutics Stock Soars on Report of $15B AstraZeneca Partnership TalksJuly 3, 2025 | msn.comAstraZeneca In Talks To License Summit Therapeutics’ Experimental Lung Cancer Drug: ReportJuly 3, 2025 | msn.comAstraZeneca considers moving listing to US, the Times reportsJuly 2, 2025 | msn.comWill AstraZeneca be the next FTSE 100 stock to move to the US?July 2, 2025 | msn.comAstraZeneca rallies Tuesday, outperforms marketJuly 1, 2025 | marketwatch.comAZN Stock Price Quote - MorningstarJuly 1, 2025 | morningstar.comMRakovina Therapeutics Highlights Strong H1 Progress and Unveils Strategic Priorities for H2 2025June 30, 2025 | uk.finance.yahoo.comEvotec (EVO) Joins NURTuRE-AKI Consortium to Advance Kidney Injury Drug DiscoveryJune 29, 2025 | msn.comAZN - AstraZeneca PLC ADR Price vs Fair Value - MorningstarJune 28, 2025 | morningstar.comMAstraZeneca (AZN) Scores FDA Approval for Datroway, First TROP2 ADC for Lung CancerJune 28, 2025 | msn.comAstraZeneca (LSE:AZN) Gains FDA Approval For Datroway In Treating Advanced Lung CancerJune 26, 2025 | uk.finance.yahoo.comAstraZeneca Presents Positive Phase I/II Data for Surovatamig in B-cell ALL at EHA 2025June 25, 2025 | msn.com Get AstraZeneca News Delivered to You Automatically Sign up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter. Email Address AZN Media Mentions By Week AZN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AZN News Sentiment▼0.750.45▲Average Medical News Sentiment AZN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AZN Articles This Week▼14▲AZN Articles Average Week Get AstraZeneca News Delivered to You Automatically Sign up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies GSK News Ithaca Energy News HUTCHMED News Indivior News Grainger News Bloomsbury Publishing News Origin Enterprises News Global Ports News India Capital Growth News Aura Energy News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (LON:AZN) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AstraZeneca PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share AstraZeneca With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AZN Stock Alerts